Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
ID: 348997Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348997

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research into the mechanisms and trajectories of schizophrenia and related disorders in individuals aged 35 and older. The initiative seeks to uncover biological, behavioral, psychosocial, and environmental factors influencing the onset and progression of these disorders, with an emphasis on identifying therapeutic targets and exploring the relationship between schizophrenia and dementia. This funding opportunity utilizes the R01 Research Project Grant mechanism, with applications due by various deadlines from October 2023 through June 2027, and is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and state or local governments. Interested parties can find more information and submission guidelines at the NIH grants website and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-023-Full-Announcement.html
    PAR-24-023.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) aimed at advancing research into schizophrenia and related disorders in mid- to late-life individuals (age 35 and older). The objective is to uncover mechanisms influencing the onset and progression of these disorders, with a focus on biological, behavioral, psychosocial, and environmental factors. This funding utilizes the R01 Research Project Grant mechanism, with a companion R21 grant for exploratory projects lacking preliminary data. Applications must follow strict submission guidelines and are due by several deadlines from October 2023 through June 2027. Eligible applicants include various higher education institutions, nonprofits, and state or local governments. The study design should emphasize diversity among research teams and adopt dimensional measures of psychopathology instead of traditional diagnostic categories. Projects should aim to identify therapeutic targets, explore the relationship between schizophrenia and dementia, and utilize cutting-edge neuroimaging techniques. The funding emphasizes the importance of data sharing and participant consent, alongside rigorous compliance with NIH policies. Successful projects will contribute significantly to understanding and improving health outcomes for those affected by schizophrenia during mid- to late-life.
    Similar Opportunities
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life" (PAR-24-026), aimed at advancing research on the onset and progression of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to promote high-risk exploratory and developmental projects that investigate neurobiological, psychosocial, and environmental factors contributing to these disorders, with a particular emphasis on addressing health disparities among minority and aging populations. The program offers a maximum funding amount of $275,000 over two years, with applications due by November 16, 2023, for the initial cycle. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research on schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to explore the mechanisms, trajectories, and outcomes of these disorders, with a focus on identifying targets for prevention and treatment interventions, particularly emphasizing the inclusion of diverse research teams and individuals with lived experience. The funding is available through the R01 grant mechanism, with applications due by September 7, 2026, and interested applicants are encouraged to adhere strictly to the application guidelines and contribute data to the National Institute of Mental Health Data Archive. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html.
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research on schizophrenia and related disorders in individuals aged 35 and older, through the R21 grant mechanism. This initiative aims to enhance understanding of the onset, trajectory, and outcomes of these disorders in mid- to late-life, encouraging innovative studies that identify biological, behavioral, and environmental risk factors, as well as potential interventions. The funding, which can reach up to $275,000 over a maximum of two years, is crucial for addressing health disparities faced by older adults with these disorders and promoting novel solutions for their care. Applications are due between January 2025 and October 2026, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for early and late-stage clinical trials focused on Alzheimer's Disease (AD) and related dementias, as well as age-related cognitive decline. This initiative aims to develop and implement both pharmacological and non-pharmacological interventions to address cognitive and neuropsychiatric changes associated with these conditions, while also encouraging innovative trial designs and methodologies. Given the significant public health crisis posed by AD, which currently affects over six million Americans, this funding opportunity is part of a broader strategy to enhance research and develop effective therapies across the disease spectrum. Applications are due by January 7, 2025, and interested parties can find more information and submit proposals through the NIH ASSIST online system or contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at advancing research on neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative encourages applications for studies that enhance understanding of the mechanisms underlying NPS, such as aggression, anxiety, and sleep disturbances, with the goal of identifying potential therapeutic targets for interventions. The funding opportunity is open to a diverse range of applicants, including universities, non-profits, and governmental agencies, with applications accepted until September 7, 2026. Interested parties can find more information and submit inquiries via email at grantsinfo@nih.gov, and further details are available at the NIH grants website.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.